Ambee Pharmaceuticals (DHA:AMBEEPHA) Total Long-Term Assets: BDT0.00 Mil (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:AMBEEPHA Ambee Pharmaceuticals Plc DHA:AMBEEPHA
18 GF Score
Price BDT813.00
View Full Analysis

What is Ambee Pharmaceuticals Total Long-Term Assets?

Ambee Pharmaceuticals DHA:AMBEEPHA -0.59% 18 Total Long-Term Assets is BDT0.00 Mil as of . 20. GuruFocus rates DHA:AMBEEPHA with a GF Score™ of 18/100.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Ambee Pharmaceuticals's Total Long-Term Assets for the quarter that ended in . 20 was BDT0.00 Mil.

Ambee Pharmaceuticals Total Long-Term Assets Related Terms

Ambee Pharmaceuticals Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Ambee Pharmaceuticals's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ambee Pharmaceuticals Total Long-Term Assets Chart

Ambee Pharmaceuticals Annual Data
Trend
Total Long-Term Assets

Ambee Pharmaceuticals Semi-Annual Data
Total Long-Term Assets
DHA:AMBEEPHA
18GF Score
Ambee Pharmaceuticals Plc DHA:AMBEEPHA
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ambee Pharmaceuticals Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of BDT0.00 Mil mean?
Ambee Pharmaceuticals (DHA:AMBEEPHA) has a Total Long-Term Assets of BDT0.00 Mil as of . 20. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Ambee Pharmaceuticals and its competitors.
Is Ambee Pharmaceuticals' Total Long-Term Assets too high?
Ambee Pharmaceuticals' current Total Long-Term Assets is BDT0.00 Mil. Overall, Ambee Pharmaceuticals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Ambee Pharmaceuticals' Total Long-Term Assets compare to IMNPQ?
Ambee Pharmaceuticals' Total Long-Term Assets of BDT0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Drug Manufacturers company?
A good Total Long-Term Assets depends on the Drug Manufacturers industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Ambee Pharmaceuticals and its competitors. Ambee Pharmaceuticals's current Total Long-Term Assets is BDT0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ambee Pharmaceuticals stock overvalued right now?
Ambee Pharmaceuticals (DHA:AMBEEPHA) has a current Total Long-Term Assets of BDT0.00 Mil. The current Total Long-Term Assets is BDT0.00 Mil. Ambee Pharmaceuticals' overall GF Score™ is 18/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Ambee Pharmaceuticals (DHA:AMBEEPHA), the current Total Long-Term Assets is BDT0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ambee Pharmaceuticals Business Description

Address 184/1 Tejgaon Industrial Area, Dhaka, BGD, 1208
Ambee Pharmaceuticals Plc formerly Ambee Pharmaceuticals Ltd manufactures a wide range of pharmaceutical products in Bangladesh. It is engaged in the business of manufacturing drugs and medicine and sales. Its products are sold in the form of tablets, capsules, liquids, gels, and injectables.
18GF Score

Get the complete analysis for DHA:AMBEEPHA

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT813.00
Price